Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised,...

Keywords

EtoposideMedicineDurvalumabPlatinumOncologyStage (stratigraphy)Internal medicineCancerChemotherapyNivolumabBiologyImmunotherapy

Affiliated Institutions

Related Publications

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

The National Lung Screening Trial: Overview and Study Design

Constantine A. Gatsonis , Denise R. Aberle , Christine D. Berg +97 more

The National Lung Screening Trial (NLST) is a randomized multicenter study comparing low-dose helical computed tomography (CT) with chest radiography in the screening of older c...

2010 Radiology 1227 citations

Publication Info

Year: 2019
Type: article
Volume: 394
Issue: 10212
Pages: 1929-1939
Citations: 2014
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2014

OpenAlex

Cite This

APA Style

                            
                                
                                    Luis Paz‐Ares, 
                                
                                    Mikhail Dvorkin, 
                                
                                    Yuanbin Chen
                                
                                et al.
                            
                            (2019). 
                            Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. 
                            The Lancet
                            , 394
                            (10212)
                            , 1929-1939.
                            https://doi.org/10.1016/s0140-6736(19)32222-6
                        

Identifiers

DOI: 10.1016/s0140-6736(19)32222-6